Higher-dose cohort builds on earlier study data, positioning the synthetic glycan vaccine for future development.
Swiss pharma company Idorsia’s synthetic glycan vaccine targeting Clostridioides difficile (C. difficile), has illustrated a positive step towards a new potential approach to vaccination, new clinical trial data shows.
Findings from the phase I study demonstrated that a high dose of Idorsia’s vaccine IDOR-1134-2831 facilitated immunogenicity, was well-tolerated and provided a good safety profile for participants.
“The dose-dependent responses against the glycan target present on both C. difficile bacteria and spores, underscore the potential of this vaccine to go beyond traditional strategies and target the full life cycle of the pathogen”
Dr Martine Clozel, Chief Scientific Officer & Head of Research at Idorsia, said: “These new results from the high-dose cohort mark an important step forward for our synthetic glycan vaccine platform and reinforce our conviction that we are pioneering a fundamentally new approach to vaccination.
“The dose-dependent responses against the glycan target present on both C. difficile bacteria and spores, underscore the potential of this vaccine to go beyond traditional strategies and target the full life cycle of the pathogen. Beyond C. difficile, this technology has the potential to transform the landscape of vaccines, allowing prophylaxis against multiple bacteria and more.
“The fact that the antigens are synthesised in a chemistry laboratory offers immense opportunity. To fully realise this potential and accelerate development, we intend to advance this programme in partnership.”
Uniquely, Idorsia’s C. difficile vaccine is stable, immunogenic, fully characterisable, and could enable scalable and cost-efficient manufacturing.
In other vaccine news, last month Eli Lilly forged ahead with padding out its infectious disease portfolio, snapping up three vaccine specialists for a total $3.8 billion.
Under the agreements, Eli Lilly gains rights to candidates from companies Curevo, LimmaTech Biologics and Vaccine Company. Specifically, the vaccines are targeting shingles, AMR-driving pathogens and Epstein-Barr Virus, respectively.
Additionally, the European Directorate for the Quality of Medicines & HealthCare (EDQM) published a single guideline for mRNA vaccines produced with lipid nanoparticles (LNPs) and two revised guidelines for vaccines to treat infectious diseases.
No comments yet